Tradestie Institutional Equity Comparison Engine
DRIO vs XBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
XBIO Overall Edge
XBIO Captures Institutional Edge (2โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xenetic Biosciences, Inc. (XBIO) driven by superior Growth & Margin, Momentum & Technical while DRIO counters with relative strength in Valuation. Fundamentally, DRIO trades at 10.6x Forward P/E with -142.7% operating margin (+6.1% YoY revenue) versus XBIO at N/M Forward P/E and -81.0% operating margin (+12.0% YoY). In options structure, DRIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against XBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
DRIO
DRIO 10.6x vs XBIO N/M Fwd P/E
Growth & Margin Winner
XBIO
Op Margin -142.7% vs -81.0% ยท YoY +6.1% vs +12.0%
Momentum & Technical Winner
XBIO
1Y -90.0% vs -44.9% ยท 52W Pos 2% vs 4%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
DRIO
NASDAQ
DarioHealth Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$1.32
-8.33% 1D
Market Cap
$16.3M
1M Return
-61.29%
1Y Return
-90.02%
Forward P/E
10.6x
Unified AI Score
42.2 / 100
HOLD
Tech 50.0
Fund 52.0
Flow 50.0
Mom 55.0
XBIO
NASDAQ
Xenetic Biosciences, Inc.
Pharmaceutical Preparations
$1.40
-9.09% 1D
Market Cap
$3.6M
1M Return
-27.46%
1Y Return
-44.88%
Forward P/E
N/M
Unified AI Score
43.5 / 100
HOLD
Tech 25.0
Fund 56.0
Flow 50.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
DRIO -90.02%
XBIO -44.88%
Spread: +45.69 pp (XBIO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
DRIO TTM Op. Margin: -142.7%
XBIO TTM Op. Margin: -81.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRIO vs XBIO. Trailing 12-month operating profitability (DRIO -142.7% vs XBIO -81.0%) and valuation multiples (DRIO 10.6x vs XBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DRIO | XBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $16.3M | $3.6M | Larger Scale | DRIO |
| Trailing P/E Ratio Valuation | 10.6x | N/M | Lower Multiple | DRIO |
| Forward P/E Ratio Valuation | 10.6x | N/M | Lower Multiple | DRIO |
| Revenue Growth (YoY) Growth | +6.1% | +12.0% | Higher Growth | XBIO |
| Operating Margin (TTM) Profitability | -142.7% | -81.0% | Higher Margin | XBIO |
| Net Profit Margin Profitability | -159.9% | -75.9% | Higher Margin | XBIO |
| Return on Equity (ROE) Capital Efficiency | -46.6% | -47.0% | Higher ROE | DRIO |
| 52-Week Range Position Momentum | 2% ($1โ$15) | 4% ($1โ$5) | Stronger Trend | XBIO |
| Beta / 30D Volatility Risk Regime | 0.45ฮฒ ยท 182% Vol | 1.40ฮฒ ยท 99% Vol | Lower Realized Risk | XBIO |
| Unified Institutional Score Composite Signal | 42.2 / 100 (HOLD) | 43.5 / 100 (HOLD) | Higher Composite | XBIO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full DRIO vs XBIO Buy Guide
DRIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
XBIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither DRIO nor XBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.